Related references
Note: Only part of the references are listed.Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial
Davey Daniel et al.
INTERNATIONAL JOURNAL OF CANCER (2021)
Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
Chao Li et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2021)
Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies
Jared Weiss et al.
CLINICAL LUNG CANCER (2021)
Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study
Lowell L. Hart et al.
ADVANCES IN THERAPY (2021)
Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer
Jeffrey Crawford et al.
SUPPORTIVE CARE IN CANCER (2020)
SEOM clinical guidelines for the treatment of small-cell lung cancer (SCLC) (2019)
M. Domine et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors
Robert S. Epstein et al.
ADVANCES IN THERAPY (2020)
Effects of the COVID-19 pandemic on supply and use of blood for transfusion
Simon J. Stanworth et al.
LANCET HAEMATOLOGY (2020)
Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice
Derek Weycker et al.
BMC CANCER (2019)
Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update
Julia Bohlius et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Real-world effectiveness and tolerability of small-cell lung cancer (SCLC) treatments: A systematic literature review (SLR)
Manca Povsic et al.
PLOS ONE (2019)
Current Diagnosis and Management of Small-Cell Lung Cancer
Shuhang Wang et al.
MAYO CLINIC PROCEEDINGS (2019)
What is the role of radiotherapy for extensive-stage small cell lung cancer in the immunotherapy era?
Eric G. Nesbit et al.
TRANSLATIONAL LUNG CANCER RESEARCH (2019)
Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial
J. M. Weiss et al.
ANNALS OF ONCOLOGY (2019)
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
Luis Paz-Ares et al.
LANCET (2019)
Transfusion practice patterns in patients with anemia receiving myelosuppressive chemotherapy for nonmyeloid cancer: results from a prospective observational study
James Granfortuna et al.
SUPPORTIVE CARE IN CANCER (2018)
Overall survival and risk of second malignancies with cancer chemotherapy and G-CSF support
G. H. Lyman et al.
ANNALS OF ONCOLOGY (2018)
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
L. Horn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines
M. Aapro et al.
ANNALS OF ONCOLOGY (2018)
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
Marc Thill et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Transient CDK4/6 inhibition protects hematopoietic stem cells from chemotherapy-induced exhaustion
Shenghui He et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population
Aniket A. Kawatkar et al.
SUPPORTIVE CARE IN CANCER (2017)
Risk Factors and Patterns of Potentially Avoidable Readmission in Patients With Cancer
Jacques D. Donze et al.
JOURNAL OF ONCOLOGY PRACTICE (2017)
Impact of chemotherapy-induced neutropenia (CIN) and febrile neutropenia (FN) on cancer treatment outcomes: An overview about well-established and recently emerging clinical data
Yassine Lalami et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Systematic analysis of design and stratification for phase III trials in first-line advanced non-small cell lung cancer
Takefumi Komiya et al.
THORACIC CANCER (2016)
Thoracic Vertebral Body Irradiation Contributes to Acute Hematologic Toxicity During Chemoradiation Therapy for Non-Small Cell Lung Cancer
Matthew P. Deek et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2016)
Current patterns of care for patients with extensive stage small cell lung cancer: Survey of US radiation oncologists on their recommendations regarding thoracic consolidation radiotherapy
Timur Mitin et al.
LUNG CANCER (2016)
Preclinical Characterization of G1T28: A Novel CDK4/6 Inhibitor for Reduction of Chemotherapy-Induced Myelosuppression
John E. Bisi et al.
MOLECULAR CANCER THERAPEUTICS (2016)
Relationship between severity and duration of chemotherapy-induced neutropenia and risk of infection among patients with nonmyeloid malignancies
Yanli Li et al.
SUPPORTIVE CARE IN CANCER (2016)
Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial
Ben J. Slotman et al.
LANCET (2015)
The five Ws for bone pain due to the administration of granulocyte-colony stimulating factors (G-CSFs)
Matteo Lambertini et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2014)
Transfusions and patient burden in chemotherapy-induced anaemia in France
Patricia K. Corey-Lisle et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2014)
The burden of blood transfusion: a utilization and economic analysis – a pilot study in patients with chemotherapy-induced anemia (CIA)
John F. Reitan et al.
JOURNAL OF MEDICAL ECONOMICS (2013)
Thoracic radiation therapy improves the overall survival of patients with extensive-stage small cell lung cancer with distant metastasis
Hui Zhu et al.
CANCER (2011)
Impact of Chemotherapy Dose Intensity on Cancer Patient Outcomes
Gary H. Lyman
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2009)
Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: A systematic review
Nicole M. Kuderer et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Economic burden of haematological adverse effects in cancer patients - A systematic review
S. Y. Liou et al.
CLINICAL DRUG INVESTIGATION (2007)
Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: Results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis - A Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study
A Ardizzoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Chemotherapy-induced neutropenia - Risks, consequences, and new directions for its management
J Crawford et al.
CANCER (2004)
Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: A nationwide study of community practices
GH Lyman et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Population-based assessment of hospitalizations for toxicity from chemotherapy in older women with breast cancer
XLL Du et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Share Paper
